0000000000247627

AUTHOR

Wolf-dieter Ludwig

showing 7 related works from this author

Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas—results of …

2006

Myeloablative radio-chemotherapy with subsequent autologous stem cell transplantation (ASCT) significantly prolongs progression free and probably overall survival in follicular lymphoma (FL) in first remission. The current trial explored prospectively the rate of successful stem cell mobilization in patients with advanced stage FL after initial therapy with either Mitoxantrone, Chlorambucil, Prednisone (MCP) or Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) as part of a prospective randomized comparison of both regimens. ASCT patients received Dexa-BEAM (Dexamethasone, BCNU, Melphalan, Etoposide, Cytarabine) for mobilization of stem cells. Stem cells were collected and a mini…

MaleOncologymedicine.medical_treatmentFollicular lymphomaLymphoma Mantle-CellHematopoietic stem cell transplantationCHOPDexamethasone0302 clinical medicineAutologous stem-cell transplantationGermanyhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularMelphalanEtoposideCytarabineHematopoietic Stem Cell TransplantationHematologyMiddle AgedHematopoietic Stem Cell Mobilization3. Good healthSurvival RateTreatment OutcomeOncologyVincristine030220 oncology & carcinogenesisFemalemedicine.drugAdultmedicine.medical_specialtyVincristinePrednisolone03 medical and health sciencesInternal medicinemedicineHumansCyclophosphamideAgedChemotherapyMitoxantronebusiness.industrymedicine.diseaseCarmustineLeukemia Lymphocytic Chronic B-CellSurgeryDoxorubicinPrednisoneChlorambucilMantle cell lymphomaMitoxantronebusiness030215 immunologyAnnals of Oncology
researchProduct

Declaration and Handling of Conflicts of Interest in Guidelines

2015

Clinical guidelines are developed in order to support physicians and patients in specific clinical situations when decisions concerning diagnosis and treatment are made. Recommendations provided in guidelines are based on the findings of clinical studies and on expert opinion. Identical study findings may be evaluated differently depending on whether or not guideline authors have conflicts of interest (1). A conflict of interest is defined as a circumstance that gives rise to a risk that professional judgement or actions concerning a primary interest may be inappropriately influenced by a secondary interest (2, 3). A conflict of interest is therefore a state of affairs, not a biased evaluat…

business.industryDownloadmedia_common.quotation_subjectDeclarationConflict of interestGeneral MedicineGuidelinePublic relationsSchool of thoughtScientific evidenceConvictionMedicinebusinessDutymedia_commonDeutsches Ärzteblatt international
researchProduct

High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia [see comments]

1989

Hairy cell leukemia (HCL) is frequently associated with severe pancytopenia. The authors detected high levels of tumor necrosis factor (TNF)-alpha in the bone marrow serum of patients with HCL and found anti-TNF-alpha neutralizing monoclonal antibodies (MoAbs) to be able to enhance hematopoiesis of HCL patients in in vitro colony assays. As potent producers of TNF-alpha, hairy cells could be identified, thus implicating the malignant population in the pathogenesis of hematopoietic failure due to inappropriate secretion of this cytokine.

education.field_of_studybusiness.industrymedicine.medical_treatmentImmunologyPopulationCell BiologyHematologymedicine.diseaseBiochemistryPancytopeniaHaematopoiesisCytokinemedicine.anatomical_structureImmunologymedicineHairy CellTumor necrosis factor alphaHairy cell leukemiaBone marrowbusinesseducationBlood
researchProduct

Combined Immuno-Chemotherapy (R-CHOP) Results in Significantly Superior Response Rates and Time to Treatment Failure in First Line Treatment of Patie…

2004

Abstract Lymphomplasmocytoid/ic immunocytoma (LP-IC), including Waldenstrom’s macro-globulinemia and lymphoplasmacytoid lymphoma according to the Kiel classification (the latter one subsummed as a variant of B-CLL in the WHO classification), is an indolent lymphoma, which is incurable by conventional chemotherapy in the advanced stage of disease. The anti-CD20 antibody Rituximab has shown remarkable activity in indolent lymphomas, in particular when combined with chemotherapy. Based on these results the GLSG investigated the efficacy of a combined immuno-chemotherapy (R-CHOP: Rituximab 375 mg/m2 d0-1; cyclophosphamide 750 mg/m2 d1; doxorubicine 50 mg/m2 d1; vincristine 1.4 mg/m2 d1; prednis…

Vincristinemedicine.medical_specialtyCyclophosphamideImmunologyCHOPBiochemistryGastroenterologyLymphoplasmacytic Lymphoma03 medical and health sciences0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesInternal medicinemedicine030304 developmental biology0303 health sciencesbusiness.industryWaldenstrom macroglobulinemiaCell BiologyHematologymedicine.disease3. Good healthSurgeryLymphomaRegimen030220 oncology & carcinogenesisRituximabbusinessmedicine.drugBlood
researchProduct

Incidence of lineage promiscuity in acute myeloblastic leukemia: Diagnostic implications of immunoglobulin and T-cell receptor gene rearrangement ana…

1988

Abstract Sixty-nine blood or bone marrow samples from both children and adults with acute myeloblastic leukemia (AML) were investigated to elucidate the frequency of immunoglobulin (IG) and T-cell receptor (TCR)-gene rearrangements. Non-germline configuration for the IG heavy chain (h) gene was detected in the specimens of nine patients of various subtypes according to the French-American-British classification (FAB), including FAB M1, M2, M4 and M5. Rearrangement of the IG kappa chain (k) gene was present in one of these cases which simultaneously revealed a rearranged TCR-beta (b) chain gene. In another two AML samples we found TCR-b gene rearrangements, in one case in combination with an…

AdultImmunoglobulin geneCancer ResearchAcute myeloblastic leukemiaCD19medicineHumansGene Rearrangement beta-Chain T-Cell Antigen ReceptorChildGenes ImmunoglobulinbiologyAntibodies MonoclonalCell DifferentiationHematologyGene rearrangementmedicine.diseaseMolecular biologyLeukemia Myeloid AcuteLeukemiaPhenotypeOncologyTerminal deoxynucleotidyl transferaseT-Cell Receptor Genebiology.proteinAntibodyImmunoglobulin Heavy ChainsLeukemia Research
researchProduct

High-level secretion of tumor necrosis factor-alpha contributes to hematopoietic failure in hairy cell leukemia [see comments]

1989

Abstract Hairy cell leukemia (HCL) is frequently associated with severe pancytopenia. The authors detected high levels of tumor necrosis factor (TNF)-alpha in the bone marrow serum of patients with HCL and found anti-TNF-alpha neutralizing monoclonal antibodies (MoAbs) to be able to enhance hematopoiesis of HCL patients in in vitro colony assays. As potent producers of TNF-alpha, hairy cells could be identified, thus implicating the malignant population in the pathogenesis of hematopoietic failure due to inappropriate secretion of this cytokine.

education.field_of_studybusiness.industrymedicine.medical_treatmentImmunologyPopulationCell BiologyHematologymedicine.diseaseBiochemistryPancytopeniaHaematopoiesismedicine.anatomical_structureCytokineCancer researchMedicineHairy CellHairy cell leukemiaTumor necrosis factor alphaBone marrowbusinesseducationBlood
researchProduct

CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)- Results of a Randomized Trial of the German Low G…

2004

Abstract In advanced stage follicular lymphoma conventional chemotherapy is non-curative and no major improvement in overall survival has been achieved by different regimens. Similarly, MCL, a lymphoma subtype with an especially poor clinical outcome, cannot be cured by conventional chemotherapy. In 1996, the German Low Grade Lymphoma Study Group (GLSG) started a randomized trial to evaluate the efficacy of two different anthracycline/anthrachinon containing regimens comparing CHOP (cyclophosphamide 750 mg/m2 day 1, vincristine 1.4 mg/m2 day 2, adriamycine 50 mg/m2 day 1, prednisone 100 mg/m2 days 1–5) and MCP (mitoxantrone 8 mg/m2 days 1–2, chlorambucil 3x3 mg/m2 days 1–5; prednisone 25 mg…

medicine.medical_specialtyVincristineImmunologyFollicular lymphomaCHOPBiochemistryGastroenterology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicine030304 developmental biology0303 health sciencesMitoxantroneChlorambucilbusiness.industryCell BiologyHematologymedicine.diseaseChemotherapy regimen3. Good healthLymphomaSurgery030220 oncology & carcinogenesisMantle cell lymphomabusinessmedicine.drugBlood
researchProduct